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AT A GLANCE COMMENTARY  
Scientific knowledge on the subject: Atopy and sensitization are established prognostic 
indicators in chronic respiratory diseases including asthma and chronic obstructive 
pulmonary disease (COPD) where they represent ‘treatable traits’. Their role in 
bronchiectasis not due to cystic fibrosis is unclear, and few studies have assessed the 
frequency of atopy in adult bronchiectasis. Reports to date are limited to single centre studies, 
relatively small cohorts and have demonstrated conflicting results. 
What this study adds to the field: We report, to our knowledge, the largest multi-centre 
study of atopy in bronchiectasis including patients from geographically distinct Asian 
(Singapore and Malaysia) and European (Scotland) cohorts. Our results illustrate high rates 
of allergic sensitization against a broad panel of allergens including house dust mite and 
fungi that correlate with worse clinical outcome. The airway inflammatory profile of 
‘sensitized bronchiectasis’ reveals novel endo-phenotypes of disease in our ‘matched’ and 
geographically distinct populations. This work demonstrates the importance of identifying 
sensitization and atopy in bronchiectasis, its clinical relevance and geographic variability. We 
further demonstrate two clinically relevant endo-phenotypes, each driven by a specific 
allergen response profile and airway immune signature: fungal-driven pro-inflammatory and 
house-dust mite driven chemokine dominant. These ‘immuno-allertypes’ are clinically 
relevant and identify ‘high risk’ subgroups of bronchiectasis where appropriate therapeutic 
intervention may be offered.   
 
Online data supplement statement: This article has an online data supplement, which is 
accessible from this issue's table of contents online at www.atsjournals.org 
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ABSTRACT: Rationale: Allergic sensitization is associated with poor clinical outcomes in 
asthma, chronic obstructive pulmonary disease and cystic fibrosis however its presence, 
frequency and clinical significance in non-CF bronchiectasis remain unclear. Objective: To 
determine the frequency and geographic variability that exists in sensitization pattern to 
common and specific allergens including house dust mite and fungi and, to correlate such 
patterns to airway immune-inflammatory status and clinical outcomes in bronchiectasis. 
Methods: Patients with bronchiectasis were recruited in Asia (Singapore & Malaysia) and 
the United Kingdom (Scotland) (n=238) forming the Cohort of Asian and Matched European 
Bronchiectasis (CAMEB) which matched recruited patients on age, gender and 
bronchiectasis severity. Specific-IgE response against a range of common allergens was 
determined, combined with airway immune-inflammatory status and correlated to clinical 
outcomes. Clinically relevant patient clusters based on sensitization pattern and airway 
immune profiles (“immuno-allertypes”) were determined. Measurements and Main 
Results: A high frequency of sensitization to multiple allergens was detected in 
bronchiectasis, exceeding that in a comparator cohort with allergic rhinitis (n=149). 
Sensitization associated with poor clinical outcomes including decreased pulmonary function 
and more severe disease. ‘Sensitized-bronchiectasis’ was classified into two ‘immuno-
allertypes’: one fungal-driven and pro-inflammatory versus house dust mite-driven, 
chemokine-dominant with the former demonstrating poorer clinical outcome. Conclusion: 
Allergic sensitization occurs at high frequency in bronchiectasis patients recruited from 
different global centres. Improving endo-phenotyping of ‘sensitized-bronchiectasis’, a 
clinically significant state, and ‘treatable trait’ permits therapeutic intervention in appropriate 
patients and may allow improved stratification in future bronchiectasis research and clinical 
trials. 
Key words: Bronchiectasis; Sensitization; Allergy; House dust-mite; Aspergillus 
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INTRODUCTION 
Bronchiectasis not due to cystic fibrosis is a disease experiencing a clinical and research 
renaissance.(1) Characterized by persistent cough, mucopurulent secretions and recurrent 
infection, permanent and irreversible bronchial dilatation ensues.(2) The failure of therapies 
used in cystic fibrosis (CF) to translate to bronchiectasis is exemplified by trials of 
recombinant DNAse therapy, which in contrast to CF, increases exacerbations in 
bronchiectasis.(3) Such failures suggest fundamental differences in disease associated 
mechanisms necessitating data-driven, endo-phenotyping approaches toward improved 
patient stratification in this heterogeneous disease.(2) While disease-associated effects on 
host immunity, infection and inflammation are recognized, the role of allergic sensitization in 
the setting of bronchiectasis lacks dedicated study. 
  
Atopy is a known risk factor for the development and/or progression of chronic respiratory 
disease including asthma, chronic obstructive pulmonary disease (COPD) and CF.(4, 5) 
While allergic bronchopulmonary aspergillosis (ABPA) is an identified cause for 
bronchiectasis, the specific role of atopy and sensitization as a consequence of disease 
remains to be established. This is particularly important as the presence of atopy; fungal-
sensitization and ABPA in asthma, COPD and CF are all recognized associations of poorer 
clinical outcome including decreased pulmonary function, more frequent exacerbations and 
even the development of bronchiectasis.(4, 6) 
 
Prior reports of atopy in bronchiectasis are small, conflicting and limited to single centres. In 
addition, none have thus far addressed the potential for geographic variation across countries 
with differing allergen exposures and climates.  
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Here, we describe the largest study of atopy in bronchiectasis to date including patients from 
clinically ‘matched’ cohorts of Asian and European origin. Sensitization to a range of 
allergens was assessed with their clinical associations and accompanying airway 
inflammatory signatures. This allows patient stratification into clinically relevant groups 
defined as ‘immuno-allertypes’; specific endo-phenotypes of ‘sensitized bronchiectasis’ with 
therapeutic implications. Some of the results of these studies have been previously reported 
in the form of abstracts (7, 8). 
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METHODS 
Study population(s) 
Patients with stable bronchiectasis, defined by British Thoracic Society (BTS) guidelines, 
were recruited across three countries as part of the CAMEB study (a cross-sectional Cohort 
of Asian and Matched European Bronchiectasis).(9, 10) Recruitment included three sites in 
Singapore (Singapore General Hospital, Changi General Hospital and Tan Tock Seng 
Hospital; n=124), one Malaysian site (UKM Medical Centre, Kuala Lumpur, Malaysia; 
n=14) and an age-, sex- and disease-severity matched group from a single European site 
(Ninewells Hospital, Dundee, UK; n=100). The study was conducted between March 2016 
and July 2017 (total CAMEB study population, n=238). All patients had radiologically 
confirmed bronchiectasis by high-resolution computed tomography (HRCT) scanning of the 
thorax interpreted in accordance with clinical practice guidelines of the BTS.(9) Patients were 
recruited during routine visits to the outpatient clinic and were clinically stable at 
recruitment. Clinical stability was defined as the absence of new symptoms and where no 
change had occurred to their bronchiectasis therapy in the preceding six-week period. 
Patients were excluded if they had a primary diagnosis of any other major respiratory 
diagnosis (asthma or COPD) (as defined by clinical symptoms and established spirometric 
criteria),(11, 12) were pregnant or breastfeeding, had active mycobacterial disease (identified 
through symptoms, chest radiograph, and sputum microbiology),(13), or were on 
chemotherapy for malignancy. Patients with any active infection requiring use of antibiotics 
or systemic corticosteroids in the four weeks preceding recruitment were also excluded. From 
the Singapore-Kuala Lumpur (SG-KL) cohort a total of n=100 patients were matched 
individually by age, sex and total bronchiectasis severity index (BSI) score (assigned at time 
of sample acquisition) to patients in the Dundee (DD) cohort (14). Patients with any prior 
history of or active ABPA (defined as meeting established ISHAM criteria including either 
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Type 1 Aspergillus skin test positivity or elevated IgE levels against A. fumigatus and 
elevated total IgE>1000IU/mL plus at least two of the following three criteria: precipitating 
or serum IgG antibodies against A. fumigatus, radiographic change consistent with ABPA or 
total eosinophil count >500 cells/µl in steroid naïve patients) at enrolment were excluded.(15) 
A separate cohort of 149 allergic rhinitis (AR) patients, among which bronchiectasis was 
excluded by radiological examination, were recruited from the Otolaryngology outpatient 
clinic at National University Hospital, Singapore, to serve as a comparator group with high 
allergic sensitization. Allergic rhinitis was confirmed by evidence of sensitization to at least 
one allergen (by skin prick or serum IgE test) using established clinical criteria.(16) The 
institutional review board of all the participating hospitals approved the study and written 
informed consent was obtained from each patient.  
 
Full details on clinical data and specimen collection, immuno-dot blot assay for specific IgE 
measurement, multiplex analysis for cytokine/chemokine quantification as well as statistics 
and data analysis are provided in the supplementary material. 
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RESULTS 
 
Clinical characteristics and patient demographics are shown in Table 1. 
 
High frequencies of sensitization to a range of allergens are detected in bronchiectasis: 
Based on prior findings from our group and others, we sought to comprehensively assess 
sensitization levels to multiple specific allergens in the CAMEB cohort (10, 17-20). 
Measured specific-IgE (sIgE) titres against house dust mite (HDM), Alternaria alternata (Alt 
a) and recombinant allergens of Aspergillus fumigatus (rAsp) revealed high frequencies of 
sensitization in patients with bronchiectasis (Figure 1). Sensitization of class 3 or above (to at 
least one allergen) was observed in 57·6% (n=137) of bronchiectasis patients compared to 
26·9% (n=40) in the AR cohort, that served as an unmatched comparator group (p < 0·0001). 
Of all allergens tested, extracts of HDM (Der p and Blo t) elicited the highest median sIgE 
titres in bronchiectasis (Figure 1, Table E1). Less than 3% (n=4) of AR patients exhibited 
sIgE titres in the ‘very high’ (class 4 and above) range versus 33·2% (n=79) in the 
bronchiectasis cohort. Only patients in the bronchiectasis group registered sIgE titres in the 
‘very high’ (class 6) range (n=35; 14·7%).  
 
Sensitization to multiple allergens associates with more severe disease and poorer lung 
function in bronchiectasis: Having identified high levels of sensitization in bronchiectasis, 
we next investigated if this was associated with disease severity and poorer clinical 
progression focusing on the primary clinical outcomes of BSI, lung function (FEV1 % 
predicted) and exacerbation rate in the prior year. Patients were categorized by the number of 
allergens to which each individual was sensitized (defined as sensitization ≥ class 3). Higher 
sIgE titres were observed in those sensitized to ≥ 2 allergens. These individuals more 
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frequently had titres in the ‘very high’ (class 4-6) range (Figure 2, p < 0·00001). Patients with 
sensitization to ≥3 allergens had greatest disease severity and poorest lung function (Figures 
2A and 2B) but no association was found with exacerbation frequency (Figure 2C). 
 
Sensitization patterns in bronchiectasis demonstrate geographic variation: In patients 
from both cohorts: SG-KL and DD, the association between sensitization and poorer lung 
function (Figure 2b) was statistically significant (p < 0·01), whereas the effect on BSI (Figure 
2a) was more pronounced in the SG-KL cohort (p <0·01) compared to the DD cohort (p = 
0·06). Interestingly, we found distinct geographic allergen response profiles based on patient 
origin. Patients from the SG-KL cohort exhibited higher responses to HDM allergens 
compared to the DD cohort, of which the response to D. pteronyssinus (Der p) was 
significant (Figure 3). In contrast, the DD cohort had greater responses to fungal allergens 
including A. alternata and A. fumigatus (rAsp f 6, f 8, f 15, f 17) with one exception, the A. 
fumigatus major allergen rAsp f 1, whose response was significantly elevated in the SG-KL 
cohort (Figure 3). In specific matched patient analyses, the significant responses to Der p and 
rAsp f 1 remained in the SG-KL cohort while the response to rAsp f 17 was the single 
relationship maintained in the DD cohort (Table E2 and E3). The clinical consequence of 
varied geographic sensitization pattern did not necessarily correlate with their observed 
frequency: sensitization to HDM allergens and rAsp f 1 were associated with poorer lung 
function in SG-KL and DD cohorts respectively, while sensitization to rAsp f 17 was only 
linked to a higher exacerbation frequency in patients from the SG-KL cohort despite its 
predominance in matched patients from the DD cohort (Table E4).  
 
Sensitization to the A. fumigatus minor allergen rAsp f 17 is enriched in bronchiectasis-
associated serological-ABPA (s-ABPA): All recruited bronchiectasis patients were 
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managed in accordance with established ERS guidelines that advise screening for ABPA at 
diagnosis: we excluded all patients that screened positive in accordance with our study 
criteria but in some cases this screening would have been several years prior.(2) Despite this 
strict exclusion criteria, when all Aspergillus-sensitized patients in our bronchiectasis cohort 
were considered (n=224; 95·8%), 43 (18·1%) met the criteria for s-ABPA based on the 
published classification used in CF-related bronchiectasis.(21)  
 
In these patients, we next assessed the relationship between the presence or absence of s-
ABPA, and sensitization to specific A. fumigatus allergens. This revealed a significant 
association between s-ABPA and a rAsp f 17 specific response, a relationship statistically 
driven by differences in the DD cohort (Figure 4A and 4B). Importantly, however, a trend 
toward enrichment of a sensitization response to rAsp f 17 was also observed in the SG-KL 
cohort (Figure 4B). When all s-ABPA patients are considered (from both SG-KL and DD 
cohorts), a significantly higher proportion have sensitization responses to rAsp f 17 in the 
class 3 or above range (Table E4). Those with rAsp f17 sensitivity also had higher rates of 
qPCR positivity for A. fumigatus  (69% vs 45%, p = 0.017) while their sputum 
galactomannan levels were comparable (65% vs 69%, p = 0.801), measures determined in 
prior reported analysis of the CAMEB cohort.(10) Interestingly, whilst the highest observed 
responses to rAsp f 17 were in Scottish patients with s-ABPA, Singaporean and Malaysians 
who had significant responses to rAsp f 17 also had significantly more exacerbations (Median 
= 1·5 versus 0; p<0·05) suggestive that responses to this allergen are clinically relevant in 
both populations (Figure 4, Table E4). 
 
Clinically relevant ‘immuno-allertypes’ are defined by sensitization pattern and airway 
immune profiling in bronchiectasis: We next investigated whether clinically relevant 
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patient clusters based on sensitization pattern and airway immune profiles (“immuno-
allertypes”) occur in bronchiectasis. To address this, we used multiplex sputum cytokine and 
chemokine profiling approach, previously validated in COPD, to assess immunological 
signals and linked this to sensitization patterns and accompanying clinical phenotypes (22). 
Hierarchical cluster analysis of resultant data revealed two distinct patient immuno-allertypes 
characterised by distinct sensitization patterns and immune profile (Figure 5A). Assignment 
into immuno-allertypes was not driven by geographic origin or the presence of s-ABPA as, 
within each group, we found equal proportions of patients from both SG-KL and DD cohorts 
as well as an equal distribution of s-ABPA (p>0·5) (Figure 5A). Each immuno-allertype was 
instead defined by a unique sensitization pattern and immune profile: patients in the fungal-
driven pro-inflammatory (FDPI) group exhibited marked responses to the fungal allergens 
Alt a and rAsp coupled to a pro-inflammatory profile characterised by elevated airway 
TNFα, IL-1α and IL-1β. Asthma-like symptoms, long-term antibiotics (p=0.0620) or 
increased ICS (p=0.932) use was not significantly apparent in either immuno-allertype (Table 
E5), nor was ICS use significantly different in those exhibiting sensitization (sIgE class ≥3, 
p=0.580). However, higher levels of sputum galactomannan, trending toward significance, 
were observed in FDPI bronchiectasis patients (p = 0·065, Table E5). In contrast, patients in 
the HDM-driven chemokine-dominant (HDCD) group exhibited lower sensitization to fungal 
allergens but significant responses to HDM allergens, that was accompanied by a chemokine-
dominant airway profile characterised by high GRO (CXCL1), MCP-1 (CCL2) and eotaxin-1 
(CCL11). This HDCD immuno-allertype also exhibited anti-inflammatory signatures 
including elevated IL-1RA, IL-10 and G-CSF (Figure 5A). Following patient stratification by 
underlying immuno-allertype, a significant association was observed of the FDPI pattern with 
bronchiectasis severity. The FDPI immuno-allertype conferred significantly worse disease 
(Figure 5B, Table E5) and poorer lung function (Figure 5C, Table E5) while frequent 
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exacerbators were equally observed in both groups (Figure 5D). Post-infective bronchiectasis 
and greater long-term antibiotic use was also apparent in the FDPI group (Table E5). 
 
Geographic patient origin drives intra-immuno-allertype variation in bronchiectasis: 
Given our observed geographic differences in sensitization pattern in bronchiectasis (Figure 
3, Table E2 and E3), we next assessed if there was intra-immuno-allertype variation, based 
on patients’ geographic origin. Our previously defined immuno-allertypes were based on 
unsupervised hierarchical clustering and categorized patients into two groups, with equal 
frequencies of patients from each of our geographic cohorts (SG-KL and DD) (Figure 5A-ii). 
To investigate intra-immuno-allertype patient variation based on geographic origin, we used 
a supervised Markov blanket approach to identify features within each immuno-allertype 
associated with SG-KL and DD respectively. As such, intra-immuno-allertype variability was 
assessed in terms of information shared between sensitization pattern, immune 
cytokine/chemokine profile and geographic patient origin (Figure 6). In the FDPI group, 
Asian origin (SG-KL cohort) was associated with a predictive set of features including 
IFNα2, TNFβ and the PDGF isoforms AA and AB/BB while European origin (DD cohort) 
correlated with greater levels of sCD40L, IL-1RA and IL-17A (Figure 6A). In the HDCD 
group, patients from the SG-KL cohort exhibited an increased MCP-3, IL-1β, PDGF-AB/BB 
and a significant HDM allergen response, while IL-9, IL-10, TGFα, MDC, Eotaxin and FGF-
2 were more predictive of DD cohort membership (Figure 6B). This suggests the existence of 
sub-groups based on geographic origin within each of the defined immuno-allertypes and 
indicates the potential clinical importance of geographic heterogeneity in bronchiectasis. The 
strongly associated HDM response identified in the SG-KL cohort (Figure 6B) is consistent 
with our earlier analyses (Figure 3) which lends further credence that immuno-allertypes are 
clinically relevant. Independent of immuno-allertype, the SG-KL and DD cohorts further 
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illustrate significant differences in airway inflammatory signature, for example elevated 
PDGF-AB/BB (p<0·0001) and MCP-3 (p<0·05) in Singaporeans and Malaysians patients, 
substantiating regional differences in immune response. Eotaxin is significantly elevated in 
‘sensitized bronchiectasis’ (p < 0·05) but no differences in inflammatory patterns are 
observed between bronchiectasis patients with different underlying aetiologies (e.g. 
idiopathic, post-infectious or other causes). 
 
DISCUSSION 
Atopy and sensitization are important ‘treatable traits’ in asthma, COPD and their associated 
overlap syndromes, but their role in bronchiectasis remains uncertain (5, 17, 23). The present 
study is the most comprehensive to date addressing this and detected high frequencies of 
sensitization to a range of specific allergens, exceeding that found in a comparator AR 
cohort, which although unmatched, served as an important positive control group of 
heightened sensitization. Sensitization has clinical implications in bronchiectasis and 
demonstrates geographic variation in allergen response pattern. Individual allergen responses 
correlate with specific clinical outcomes in bronchiectasis including FEV1 (HDM and rAsp f 
1), exacerbations (rAsp f 17) and the presence of s-ABPA (rAsp f 17). Two clinically 
relevant ‘immuno-allertypes’ are described: fungal-driven, pro-inflammatory (FDPI) and 
HDM-driven, chemokine dominant (HDCD), with the FDPI pattern linked to poorer clinical 
outcome. 
 
Sensitization induced by HDM is common and may associate with poor clinical outcomes in 
allergic respiratory disease.(4, 24) The effect of HDM exposure in asthma, for instance, 
relates to a Th2-mediated, chemokine-associated allergic response of deleterious clinical 
consequence.(24, 25) In COPD, increased sensitization is implicated in disease pathogenesis 
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and correlates to exacerbations.(5) In our work, significant numbers of apparently stable 
bronchiectasis patients show HDM-sensitization which presumably reflects either co-existing 
subclinical allergic airways disease or a predisposition to atopy following airway damage 
caused by bronchiectasis. Given the dearth of bronchiectasis therapy currently available and 
the known implications of allergic sensitization on clinical outcomes in other respiratory 
diseases, addressing HDM sensitization in bronchiectasis offers an important therapeutic 
avenue. The role of fungal allergy in respiratory disease is well recognized and fungal 
sensitization is an established prognostic indicator in severe asthma with fungal sensitization 
(SAFS) and ABPA, and has also been reported in COPD where specific fungal responses are 
implicated as a risk factor for progression to bronchiectasis.(4, 17, 23) This latter work 
supports our findings of high rates of atopy and sensitization in bronchiectasis highlighting a 
potential role for A. fumigatus even in non-ABPA respiratory disease.(6, 17) Our 
comprehensive immune-allergy assessment of stable bronchiectasis patients importantly 
identified patients with s-ABPA; a potentially treatable condition, which would have been 
missed by guideline-recommended screening alone particularly as the s-ABPA developed 
after the initial diagnosis of bronchiectasis. 
 
Allergen-based sensitization patterns exhibit regional and global variability and marked 
differences have been observed across Asian and European populations.(4, 24, 26) Our group 
has previously reported a high prevalence of HDM sensitization in the Asian setting; a 
feature confirmed in bronchiectasis.(23, 26) Allergen exposure varies by country and with 
different ethnic backgrounds and, as such, a key strength of our study is in its multicentre 
design. Geographically distinct allergen profiles were observed across our matched cohorts, 
not just to HDM but also to A. alternaria and specific A. fumigatus allergens. To our 
knowledge, this is the first study to compare such populations in bronchiectasis. Singapore 
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and Malaysia (where our Asian patients were recruited) have tropical climates and distinct 
allergen profiles, which, when coupled to genetic and other environmental differences 
including air quality and use of air-conditioning, may potentially explain the observed 
differences compared to temperate oceanic climates seen in Scotland (where our European 
patients were recruited).(4, 24) Differences in sensitization between populations (for instance, 
to the same A. fumigatus specific allergen) may be due to host genetic and immunological 
variation, but allergen cross-reactivity with other fungi may also be important, given the 
potential contrasting environmental exposures. Further, B. tropicalis (Blo t) sIgE responses 
were observed amongst the European population despite the absence of this tropical dust mite 
species in Dundee. We suspect this is due to the recognition of cross reactive epitopes of D. 
pteronyssinus or other HDM species rather than those of B. tropicalis.  Critically, our 
observed allergen-associated patterns relate differently to clinical outcomes in the two 
regions: HDM and rAsp f 1 responses relate to FEV1 in Asians and Europeans respectively 
while increased exacerbations were linked to the rAsp f 17 response in Asians and to s-ABPA 
in both populations. An improved understanding of the role of environmental exposures and 
its geographic variation will ultimately require a more direct environmental measurement of 
patient exposure, preferably at the point of sampling, to fully explicate the precise influence a 
patient’s environment may have on sensitisation and disease progression in bronchiectasis. 
 
A response to rAsp f 17 is of particular importance in bronchiectasis. This allergen, encoded 
by the Afu4g03240 gene of the A. fumigatus AF293 genome, was originally characterised by 
Yuen et al. as the first species-specific antigenic cell wall galactomannoprotein,(27) but its 
clinical relevance outside invasive aspergillosis is unclear. Our study, therefore, also 
represents the first clinical evidence of a potential role for this allergen in chronic airways 
disease, and specifically in bronchiectasis where it is linked to exacerbations and s-ABPA. 
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Interestingly, Gibbons and colleagues demonstrate that rAsp f 17 exhibits significant up-
regulation (>200-fold) in A. fumigatus biofilms, much more than any other specific 
allergen.(28) Taken together; this links rAsp f 17 sensitization with A. fumigatus biofilm 
production and matrix galactomannan concentration. Therefore, further work is now 
warranted to better understand its role in immuno-pathogenesis and potential clinical use in 
Aspergillus-associated allergic disease.  
 
When sensitization pattern and airway immune response are considered together in 
unsupervised analyses, two distinct immuno-allergic signatures of clinical relevance emerge. 
The first of these groups - FDPI - is fungal-driven, characterised by specific responses to 
rAsp allergens and an airway rich in the pro-inflammatory cytokines IL-1α, IL-1β and TNF-
α. These cytokines trigger release of intercellular-adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) from the endothelium leading to neutrophil and 
eosinophil airway recruitment, and their expression in the FDPI group is notable given the 
central importance of neutrophils in bronchiectasis (29-32). Following cell recruitment, 
increased airway smooth muscle contractility and hyper-responsiveness may result, 
potentially explaining the poorer lung function and increased bronchiectasis severity in this 
group. This contrasts the HDM-associated (HDCD) immuno-allertype identified by specific 
responses to Der p and Blo t and an airway rich in chemokines (eotaxin, IP-10), lymphokines 
(IL-9, IL-2), growth factors (TGF-α) and elevated concentrations of Th2-related cytokines 
(IL-5, IL-10 and IL-13) consistent with Th2-dominant airway inflammation, suggestive of 
eosinophilic involvement. Taken together, these identified endo-phenotypes of bronchiectasis 
may be amenable to targeted treatments including anti-inflammatories, corticosteroids, anti-
Th2-cytokine or antifungal therapy; a strategy which has shown positive outcomes for CF 
patients colonized by A. fumigatus (33). Frequent exacerbators were seen in both immuno-
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allertypes with equal frequency suggesting that this important phenotypic endpoint used in 
clinical trials of bronchiectasis therapies may be underpinned by alternate mechanisms 
necessitating more targeted approaches. Though the idea that different immunological 
pathways could drive sensitization and exacerbations in bronchiectasis is intriguing, we 
recognise that our study is limited by its size. Smaller sub-groups associated with 
exacerbations may exist which our study lacked power to detect. Notwithstanding this, the 
fact that exacerbation rates were equivalent among the different immuno-allertypes serves to 
highlight that potential ‘exacerbation types’ may exist in bronchiectasis, analogous to 
observations in COPD and asthma, where potentially ‘treatable traits’ include specific 
endotype-driven exacerbations.(1, 34-36). Moreover, while exacerbation remains an key 
bronchiectasis phenotype, its use as an endpoint in clinical trials for bronchiectasis has 
proven challenging (37, 38). ‘Treatable traits’ like ‘sensitised bronchiectasis’ do not 
themselves represent clinical endpoints, however, identifying such endo-phenotypes, 
amenable to focused therapy addresses other important clinical symptoms in 
bronchiectasis.(1, 39-41) Our distinct immunoallertypes, when assessed together with 
bronchiectasis symptomology, may allow better patient stratification, which in turn permits 
tailored focused and effective interventions for this highly heterogeneous disease. 
 
A limitation of this work is its cross-sectional nature, precluding assessment of the temporal 
dynamics of the identified immuno-allertypes, their risk factors and underlying causal 
mechanisms. Our ability to assess cause-effect relationships between sensitisation and 
clinical outcome was largely constrained by our decision to focus on matching our patient 
cohorts on age, sex and disease severity, which by nature creates logistical challenges for 
longitudinal sampling. Longitudinal studies in bronchiectasis are nonetheless an important 
and an on-going research focus of our group and others, as we seek to explicate further the 
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clinical correlates of immuno-allertype profiles as well the as therapeutic factors, such as 
long-term macrolide therapy, which may influence the immuno-allertype itself through 
immunomodulation. Such effects were likely undetected in this study due to its cross-
sectional design. Further, we did not perform analyses in other comparator pulmonary 
cohorts such as asthma or assess sputum immune cells, which would have further 
substantiated the observed immuno-allertypes, and while we identified an increasing trend in 
galactomannan sputum positivity in FDPI patients, we did not investigate corresponding 
airway markers in the HDCD group such as dust mite protease. Though our allergen panel 
was broad, it can be further extended to include cockroach, animal dander or geographically 
prominent pollens – all of which are areas of future work.  
 
Bayesian network analysis revealed specific immune-profiles among our geographically 
distinct cohorts, suggesting regional variability within immuno-allertypes with implications 
for endo-phenotyping in bronchiectasis. In the SG-KL cohort, the FDPI immuno-allertype 
had associated features linked to an airflow-limiting airway remodelling process, notably 
PDGF and TNF-β expression. In contrast, patients from the DD cohort exhibiting the FDPI 
immuno-allertype had distinctive immune signatures comparable to those observed in allergic 
asthma implicating IL-RA and IL-17A.(42-44) Both geographic groups classed as HDCD 
demonstrated a chemokine-dominant, pro-inflammatory milieu with increased growth factor 
expression reflective of a fibrotic airway remodelling process. The implication of PDGF-
AB/BB is of particular interest given the recently described haematopoietic potential of the 
lung and reported links between exacerbation and platelets in COPD.(45, 46) Though 
interesting, replication of these geographic differences in larger cohorts is required before 
true clinical importance can be established. Perhaps more intriguing was the degree of 
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similarity seen across such geographically distinct populations, serving to broadly validate 
the observed immuno-allertypes and their association with clinical outcome in bronchiectasis. 
The interplay between allergens, sensitization and the immune-inflammatory response in 
bronchiectasis is complex with apparent geographical variation. Our work reveals, for the 
first time, high frequencies and distinct patterns of sensitization in bronchiectasis. While 
therapies employed in other allergic respiratory diseases may now be considered in patients 
with bronchiectasis complicated by allergic sensitization, we must address the significant and 
inherent heterogeneity in this disease. The immuno-allertypes presented here represent an 
important starting point of future work focusing on improved patient endo-phenotyping in 
bronchiectasis, which in turn will allow stratified therapeutic approaches to ‘sensitized 
bronchiectasis’: a key treatable trait. 
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Table 1. Demographic table illustrating patient cohorts of allergic rhinitis (n=149) compared 
to the CAMEB cohort of non-CF bronchiectasis (n=238). 
 
Characteristic 
 
 
Bronchiectasis 
patients (n=238) 
Bronchiectasis 
patients  
SG-KL (n=138) 
Matched cohorts 
Allergic rhinitis 
(n=149) 
SG-KL 
(n=100) 
DD 
(n=100) p-value 
Age : median (IQR) 28 (23-35) 68 (64-71) 65 (58-73) 65 (58-74) 69 (64-76) 0.021  
Gender : n (%)          0.392  
Female 60 (40%) 130 (55%) 77 (55%) 59 (59%) 53 (53%) 
Male 89 (60%) 108 (45%) 61 (45%) 41 (41%) 47 (47%) 
Aetiology n (%)      0.040 
Idiopathic - 145 (61%) 85 (62%) 63 (63%) 60 (60%)  
Post-infection (non-mycobacterial) - 51 (21%) 25 (18%) 18 (18%) 26 (26%)  
Post-infection (mycobacterial) - 19 (8%) 18 (13%) 9 (9%) 1 (1%)  
Other - 23 (10%) 10 (7%) 10 (10%) 13 (13%)  
Smoking status n (%)      0.013 
Never - 170 (70%) 108 (78%) 80 (80%) 62 (62%)  
Current - 11 (5%) 7 (5%) 4 (4%) 4 (4%)  
Past - 57 (25%) 23 (17%) 16 (16%) 34 (34%)  
BSI status : n (%)          0.355  
Severe - 147 (62%) 84 (61%) 63 (63%) 63 (63%) 
Moderate - 71 (30%) 45 (33%) 26 (26%) 26 (26%) 
Mild - 20 (8%) 9 (6%) 11 (11%) 11 (11%) 
BSI score : median (IQR) - 9 (6-13) 10 (7-14) 10 (7-14) 9 (6-12) 0.054 
BMI (kg/m2) : median (IQR) - 21 (18-27) 19 (17-22) 19 (17-22) 27 (22-31) <0.001 
MRC dyspnea score : n (%)            
1-3 - 200 (84%) 121 (88%) 90 (90%) 79 (79%) 0.001 
4 - 26 (11%) 10 (7%) 6 (6%) 16 (16%) 
5 - 12 (5%) 7 (5%) 4 (4%) 5 (5%) 
FEV1 % predicted: : median (IQR) - 74 (54-87) 69 (51-84) 69 (52-84) 76 (57-96) 0.067 
Radiological severity : n (%)          0.123 
1-2 lobes involved - 106 (45%) 62 (45%) 43 (43%) 44 (44%) 
3 or more lobes involved - 132 (55%) 76 (55%) 57 (57%) 56 (56%) 
No. of exacerbations in previous year : n (%)          <0.001 
0 - 84 (35%) 69 (50%) 44 (44%) 15 (15%) 
1-2 - 82 (35%) 51 (37%) 41 (41%) 31 (31%) 
3 or more - 72 (30%) 18 (13%) 15 (15%) 54 (54%) 
Hospital admissions before study : n (%)          0.004 
Yes - 88 (37%) 63 (46%) 43 (43%) 25 (25%) 
No - 150 (63%) 75 (54%) 57 (57%) 75 (75%) 
Colonization with other organisms : n (%)          0.002 
Yes - 127 (53%) 60 (43%) 44 (44%) 67 (67%) 
No - 111 (47%) 78 (57%) 56 (56%) 33 (33%) 
Pseudomonas colonisation : n (%)           0.032 
Yes - 23 (10%) 18 (13%) 15 (15%) 5 (5%) 
No - 215 (90%) 120 (87%) 85 (85%) 95 (95%)  
Bronchodilator use n (%)      0.158 
Yes - 107 (45%) 58 (42%) 39 (39%) 49 (49%)  
No - 131 (55%) 80 (58%) 61 (61%) 51 (51%)  
Inhaled corticosteroids n (%)      <0.001 
Yes - 80 (34%) 21 (15%) 14 (14%) 59 (59%)  
No - 158 (66%) 117 (85%) 86 (86%) 41 (41%)  
Mucolytics n (%)      <0.001 
Yes - 118 (50%) 60 (44%) 45 (45%) 13 (13%)  
No - 120 (50%) 78 (56%) 55 (55%) 87 (87%)  
Long-term antibiotics n (%)      0.032 
Yes - 48 (20%) 22 (16%) 14 (14%) 26 (26%)  
No - 190 (80%) 116 (84%) 86 (86%) 74 (74%)  
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 Table 1: Demographic table illustrating the patient cohorts with allergic rhinitis (n=149) and 
non-CF bronchiectasis (n=238). The non-CF bronchiectasis cohort includes a matched cohort 
of patients from Singapore-Kuala Lumpur (SG-KL) and Dundee (DD). Matching was 
performed based on age, gender and disease severity (total score on the bronchiectasis 
severity index; BSI). The variables defining the composite BSI score include: Body Mass 
Index (BMI), shortness of breath (MRC) dyspnea score, forced expiratory volume in the 1
st
 
second (FEV1) % predicted values, Radiological severity by number of involved lobes, 
number of exacerbations and hospitalizations in the preceding year, microbial colonization 
with other organisms and colonization by P. aeruginosa are illustrated. Relevant therapy is 
documented including bronchodilator, inhaled corticosteroid, mucolytic or long-term 
prophylactic antibiotic use. Data are presented as median (interquartile range; IQR) or 
number of patients (n) (percentage; %) and p-values for differences observed between 
matched cohorts indicated in the rightmost column. 
 
FIGURE LEGENDS 
Figure 1: High frequencies of sensitization to house dust mite (HDM), Alternaria alternata 
(Alt a) and recombinant allergens of Aspergillus fumigatus (rAsp) are detected in stable non-
cystic fibrosis (CF) bronchiectasis. Studied allergens are denoted as follows; HDM 
(Dermatophagoides pteronyssinus [Der p], Blomia tropicalis [Blo t]), Alternaria alternata 
(Alt a), and rAsp (f 1, f 2 [Major allergens] and f 6, f 8, f 15, f 17 [minor allergens]). Specific 
immunoglobulin-E (sIgE) titres (as kU/L) against each allergen are indicated: Bronchiectasis 
(B; black) and Allergic Rhinitis (AR; grey). Median values for all groups are illustrated (red 
lines).  
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Figure 2: Sensitization to multiple (≥3) allergens in non-CF bronchiectasis is associated with 
more severe disease and poorer pulmonary function but does not  effect  exacerbations. The 
number of allergens to which an individual is sensitized (defined as sIgE class ≥3) was 
examined in relation to (A) disease severity (as bronchiectasis severity index; BSI), (B) 
pulmonary function (as percent predicted forced expiratory volume in the first second; FEV1) 
and (C) exacerbation frequency in the preceding year. Dot coloration indicates specific sIgE 
class range as: non-diseased to moderate sensitization (Class 0-2; grey); high to very high 
(Class 3-4; purple) and very high (Class 5-6; pink). For patients exhibiting sensitization to 
more than a single allergen, the colouration corresponding with the highest sIgE class range 
is illustrated. Median values for all groups are shown (black lines). ns : non-significant, * p ≤ 
0·05. 
 
Figure 3: Geographic variation in sensitization profiles to specific recombinant allergens are 
observed in non-CF bronchiectasis. Patients from the SG-KL cohort  (red dots) exhibit 
significantly higher sIgE titres to D. pteronyssinus (Der p) and the major A. fumigatus 
allergen rAsp f 1 while patients from the DD cohort (blue dots) have higher responses to A. 
alternata (Alt a) and all minor Aspergillus allergens (rAsp f 6, f 8, f 15 and f 17). Median 
values for all groups are shown (black lines). * p ≤ 0·05, **p ≤ 0·01.  
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Figure 4: Sensitization to rAsp f 17 is enriched in serologic allergic bronchopulmonary 
aspergillosis (s-ABPA). (A) Specific-IgE (sIgE) titres against recombinant A. fumigatus 
allergens (major: f 1 and f 2 and minor: f 6, f 8, f 15 and f 17) in the absence or presence of s-
ABPA (N and A respectively) illustrates enrichment for significant responses to rAsp f 17 in 
s-ABPA and (B) significant sensitization to rAsp f 17 is observed in the DD (blue dots) but 
not SG-KL (red dots) cohorts with s-ABPA. Median values for all groups are shown (black 
lines). rAsp f: recombinant A. fumigatus allergen, ns: non-significant ,*p ≤ 0·05, **p ≤ 0·01. 
 
Figure 5: Pattern of allergen sensitization and associated airway inflammatory state defines 
clinically relevant immunological clusters of allergy in non-CF bronchiectasis 
(“immunoallertypes”). (A) Hierarchical cluster analysis based on systemic specific-IgE 
(sIgE) titre against a range of allergens and airway cytokine/chemokine expression reveals 
two distinct clusters (“immunoallertypes”) in bronchiectasis: FDPI (cluster 1) and HDCD 
(cluster 2). A dendrogram illustrating hierarchical clustering of bronchiectasis patients’ and 
their associated immune profiles (by heat-map) are illustrated. Coloured bars (below 
dendrogram) denote (i) cluster membership (cluster 1: purple, cluster 2: turquoise); (ii) 
geographic patient origin (SG-KL: red; DD: blue) and (iii) serologic allergic 
bronchopulmonary aspergillosis (s-ABPA) status (non-ABPA: orange; s-ABPA: green). 
Membership of Cluster 1 is associated with (B) increased disease severity (based on 
bronchiectasis severity index; BSI) and (C) poorer pulmonary function (as percent predicted 
forced expiratory volume in the 1
st
 second; % predicted FEV1) however (D) no difference in 
exacerbation frequency was detected between clusters. ns: non-significant; *p ≤ 0·05, **p ≤ 
0·01. 
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Figure 6: Geographic origin associates with intra-cluster variation in immune profiles that 
distinguish bronchiectasis patients of Asian and European origin. Mutual information 
networks illustrating associations between immune profile and geographic patient origin are 
shown for (A) cluster 1: FDPI and (B) cluster 2: HDCD. A central circle represents the target 
node of geographic patient origin (SG-KL: red or DD: blue) and positively correlated 
immune profiles (by Pearson correlation) are represented by outer circles (sized to reflect the 
mutual information shared with the target node). Line thickness illustrates the strength of the 
correlation and line colouration indicates geographic origin: SG-KL (red) and DD (blue) 
respectively. Cytokines and chemokines (white outer circles) and allergens (grey outer 
circles) are shown. Immune analytes common to both networks are further highlighted by a 
thickened border. 
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Online Data Supplement 
 
DISTINCT ‘IMMUNO-ALLERTYPES’ OF DISEASE AND HIGH FREQUENCIES OF 
SENSITISATION IN NON-CYSTIC-FIBROSIS BRONCHIECTASIS 
 
SUPPLEMENTARY MATERIALS AND METHODS  
Ethical approval: This study was approved by the institutional review boards of all 
participating institutes as follows: CIRB 2016/2073 mutually recognized by DSRB; NTU 
IRB-2016-01-031; UKMMC FF-2016-440; NHD 12/ES/0059; NHG DSRB B/04/055 and 
NUS IRB 07-023. 
 
Clinical data and specimen collection: Disease severity of each bronchiectasis patient was 
assigned according to the BSI and further divided into ‘Mild’ (BSI; 0-4), ‘Moderate’ (BSI; 5-
8) or ‘Severe’ (BSI; 9 and above) (1). These disease categories served as the basis for disease 
severity matching of cohorts of Asian and European origin in the CAMEB study as 
described.(2) Target samples sizes of matched cohorts were estimated at 100 patients per 
group based on detection of modest effect sizes of 0.5 for sensitization with >90% power. All 
clinical data comprising the BSI including age, Body Mass Index (BMI), Medical Research 
Council (MRC) dyspnea score, FEV1 percentage predicted values, radiological severity, 
number of exacerbations (defined by BTS consensus criteria) in the preceding year, 
hospitalizations in the preceding year, microbial colonization with other organisms and 
colonization by P. aeruginosa was recorded for each patient, as was data on gender, disease 
etiology and smoking status (1, 3). Data on use of bronchodilators, inhaled corticosteroids, 
mucolytics and long-term prophylactic antibiotics was also recorded, together with a range of 
molecular assays including sIgE response to crude Aspergillus extract, Anti-Aspergillus IgG 
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response, qPCR-based assessment of Aspregillus presence and sputum galactomannan assays 
as described elsewhere.(2) Spontaneously expectorated ‘representative’ sputum from a deep 
cough with the assistance of a chest physiotherapist (where appropriate) was collected in 
sterile containers and transported (on ice) for evaluation (4). All CAMEB specimens from 
clinical sites were transported promptly, appropriately and processed centrally in Singapore 
to ensure consistency and standardization of all experimental work. To ensure quality control 
of materials transported from sites outside Singapore, specimens were temperature controlled 
and their integrity checked on arrival to Singapore before experimental use.  
 
Immuno-dot blot assay for specific IgE (sIgE) measurement: The specific IgE (sIgE) 
response to crude protein extract from Dermatophagoides pteronyssinus (Der p), Blomia 
tropicalis (Blo t), Alternaria alternata (Alt a) and recombinant protein of A. fumigatus were 
assessed using an immuno-dot blot assay previously described.(5-9) The recombinant 
proteins used were rAsp f 1 (M83781), rAsp f 2 (U56938), rAsp f 6 (U53561), rAsp f 8 
(AJ224333), rAsp f 15 (AJ002026) and rAsp f 17 (AJ224865). Briefly, 1µg/ml of each 
allergen was blotted in duplicate on nitrocellulose membranes, with serially diluted IgE 
concentrations (1000 IU/mL to 0·195 IU/mL; National Institute for Biological standards) as a 
standard. One microgram of Bovine Serum Albumin (BSA) and elution buffers were used as 
negative controls. Membranes were air-dried prior to blocking with 1X PBS 0·1% Tween-20 
for an hour and incubated overnight with diluted serum (1:10 in PBS) at 4°C. Subsequently, 
the membranes were washed with 1X PBS 0·05% Tween-20 and incubated for two hours 
with anti-human IgE antibodies conjugated with alkaline phosphatase. Alkaline phosphatase 
activity was detected by adding nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3'-
indolyphosphate (BCIP) solution (Thermo Fisher Scientific) for 10 minutes. The intensities 
of the spots were recorded and measured using Syngene imaging software. Spot intensities 
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were calculated after removing background scores and inter- and intra assay concordances of 
90% and 95% respectively were observed demonstrating strong assay reproducibility. The 
levels of sIgE were categorized into class 0 to 6; class 0: ≤0·35 kU/L, class 1: 0·36-0·69 
kU/L, class 2: 0·70-3·49 kU/L, class 3: 3·50-17·40 kU/L, class 4: 17·50-49·0 kU/L, class 5: 
50-99 kU/L and class 6: ≥100 kU/L. A value of >0·35 kU/L is considered positive while ≥3·5 
kU/L considered high. 
 
Anti-Aspergillus IgG: Serum anti-Aspergillus specific Immunoglobulin-G (IgG) antibodies 
were measured using the Platelia Anti-Aspergillus IgG kit (Bio-rad) according to the 
manufacturer’s instructions. The assay detection range was 0-80 AU/mL and all samples 
were run in duplicate with a set of Aspergillus IgG calibrating standards run on each 
microplate. Observed readings were assessed in combination with those of sIgE titres against 
Aspergillus recombinant allergen in the definition of serological Allergic Bronchopulmonary 
Aspergillosis (s-ABPA) based on immunological breakpoints for Aspergillus sIgE of >0·35 
kU/L and Aspergillus specific IgG of >5 AU/ml.  
 
Sputum galactomannan assay: Aspergillus-associated sputum GM antigen was measured 
using the Platelia Aspergillus Ag kit (Biorad) according to the manufacturer’s instructions 
and as previously described with samples run in duplicate and values ≥ 0·5 considered 
positive.(10)  
 
Multiplex analysis for cytokine/chemokine quantification in sputum: Sputum expression 
levels of 41 different cytokines and chemokines were determined using the MILLIPLEX 
Human Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore) following previously 
described methodology (11). For analysis, 25µL of sample supernatant from sputum pre-
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treated with sputasol and protease inhibitor (Thermo Scientific) was used. Samples were 
incubated for 30 minutes with streptavidin-R-phycoerythrin conjugate, as per manufactures 
instruction, and analyzed with a Flexmap 3D instrument using Bio-Plex Manager software, 
v4·1 (Bio-Rad). The concentrations of each individual analyte were normalized to the total 
protein concentration in sputum which was determined by Bradford assays (Bio-rad). 
Statistics and data analysis: Data were analyzed using Prism (version 7, GraphPad 
Software), R (version 3·2·4, R Foundation for Statistical Computing) and BayesiaLab 
software (BayesiaLab 7, Bayesia S.A.S). The Shapiro-Wilk normality test was used to 
examine data distributions. All continuous variables assessed deviated significantly from 
normality and hence median values with interquartile range (IQR) are reported. Continuous 
variables were analyzed using the Mann-Whitney U and Kruskal-Wallis tests as appropriate. 
Categorical variables were compared using Fisher’s exact test or Chi-square test as 
appropriate. P-values of <0·05 were considered significant with Benjamini-Hochberg 
correction for multiple comparisons applied as appropriate. Data from the MILLIPLEX 
Human Cytokine/Chemokine Magnetic Bead Panel was adjusted for batch variation using the 
R package ‘MdimNormn’.(12) Normalized data was combined with sIgE allergen titre values 
generating a single dataset. Log-transformed values for each immunological analyte were 
scaled and visualized as hierarchically clustered heat maps using the R package 
‘heatmap.plus’, while the optimal number of clusters present in the dataset was assessed 
using the ‘NbClust’ R package. To determine potentially complex associations between 
immunological analytes and target nodes of interest (i.e. geographic origin) within identified 
clusters, Bayesian network analysis based on information theory rather than classical 
statistical modelling was employed. Discretization of variables by supervised multivariate 
analysis was performed after which a Markov-blanket-based model was implemented using 
BayesiaLab 7.(13) A Bayesian network based on all immunological measures was 
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constructed, keeping the features that made the target node conditionally independent of all 
other nodes in the model. Immune measures (‘features’), which were predictive of the target 
node (geographic origin) in the network, were thus identified. 
  
Page 40 of 48 AJRCCM Articles in Press. Published on 28-September-2018 as 10.1164/rccm.201807-1355OC 
 Copyright © 2018 by the American Thoracic Society 
REFERENCES 
1. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, 
Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT. The bronchiectasis 
severity index. An international derivation and validation study. Am J Respir Crit 
Care Med 2014; 189: 576-585. 
2. Mac Aogáin M, Chandrasekaran R, Lim Yick Hou A, Teck Boon L, Liang Tan G, Hassan 
T, Thun How O, Hui Qi Ng A, Bertrand D, Yu Koh J, Lei Pang S, Yang Lee Z, Wei 
Gwee X, Martinus C, Yie Sio Y, Anusha Matta S, Tim Chew F, Keir HR, Connolly 
JE, Arputhan Abisheganaden J, Siyue Koh M, Nagarajan N, Chalmers JD, Chotirmall 
SH. Immunological Corollary of the Pulmonary Mycobiome in Bronchiectasis: The 
Cameb Study. Eur Respir J 2018. 
3. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline 
Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 
65 Suppl 1: i1-58. 
4. Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG. 
Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations 
in cystic fibrosis. Chest 2010; 138: 1186-1195. 
5. Kidon MI, Chiang WC, Liew WK, Ong TC, Tiong YS, Wong KN, Angus AC, Ong ST, 
Gao YF, Reginald K, Bi XZ, Shang HS, Chew FT. Mite component-specific IgE 
repertoire and phenotypes of allergic disease in childhood: the tropical perspective. 
Pediatr Allergy Immunol 2011; 22: 202-210. 
6. Chan SL, Ong ST, Ong SY, Chew FT, Mok YK. Nuclear magnetic resonance structure-
based epitope mapping and modulation of dust mite group 13 allergen as a 
hypoallergen. J Immunol 2006; 176: 4852-4860. 
7. Chan SL, Ong TC, Gao YF, Tiong YS, Wang de Y, Chew FT, Mok YK. Nuclear magnetic 
resonance structure and IgE epitopes of Blo t 5, a major dust mite allergen. J Immunol 
2008; 181: 2586-2596. 
8. Gao YF, Wang de Y, Ong TC, Tay SL, Yap KH, Chew FT. Identification and 
characterization of a novel allergen from Blomia tropicalis: Blo t 21. J Allergy Clin 
Immunol 2007; 120: 105-112. 
9. Batard T, Hrabina A, Bi XZ, Chabre H, Lemoine P, Couret MN, Faccenda D, Villet B, 
Harzic P, Andre F, Goh SY, Andre C, Chew FT, Moingeon P. Production and 
proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus 
and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol 
2006; 140: 295-305. 
10. Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW. Novel 
immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin 
Immunol 2013; 132: 560-566 e510. 
11. Pedersen F, Holz O, Lauer G, Quintini G, Kiwull-Schone H, Kirsten AM, Magnussen H, 
Rabe KF, Goldmann T, Watz H. Multi-analyte profiling of inflammatory mediators in 
COPD sputum--the effects of processing. Cytokine 2015; 71: 401-404. 
12. Hong MG, Lee W, Nilsson P, Pawitan Y, Schwenk JM. Multidimensional Normalization 
to Minimize Plate Effects of Suspension Bead Array Data. J Proteome Res 2016; 15: 
3473-3480. 
13. Tsamardinos I, Aliferis CF, Statnikov AR. Algorithms for Large Scale Markov Blanket 
Discovery. In: Russell I, Haller SM, editors. FLAIRS Conference: AAAI Press; 2003. 
p. 376-381. 
Page 41 of 48  AJRCCM Articles in Press. Published on 28-September-2018 as 10.1164/rccm.201807-1355OC 
 Copyright © 2018 by the American Thoracic Society 
 SUPPLEMENTARY TABLES AND LEGENDS 
Table E1 
Allergen  Median sIgE (IQR) kU/L 
Class n (%) 
0 1 2 3 4 5 6 
House  dust mite 
Der p 2·28 (1·16-9·32) 6 (2·5) 23 (9·7) 118 (49·6) 49 (20·6) 20 (8·4) 5 (2·1) 17 (7·1) 
Blo t 2·33 (1·12-9·27) 14 (5·9) 17 (7·1) 109 (45·8) 56 (23·5) 15 (6·3) 8 (3·4) 19 (8) 
Alternaria Alt a 0·74 (0·39-1·30) 51 (21·4) 58 (24·4) 112 (47·1) 12 (5) 5 (2·1) 0 0 
Aspergillus  
Major 
rAsp f 1 0·82 (0·33-2·51) 62 (26) 40 (16·8) 95 (39·9) 29 (12·2) 6 (2·5) 3 (1·3) 3 (1·3) 
rAsp f 2 0·91 (0·52-1·59) 41 (17·2) 47 (19·8) 120 (50·4) 14 (5·9) 9 (3·8) 2 (0·8) 5 (2·1) 
Minor 
rAsp f 6 0·81 (0·46-1·42) 42 (17·6) 52(21·9) 123 (51·7) 10 (4·2) 6 (2·5) 1 (0·4) 4 (1·7) 
rAsp f 8 0·86 (0·51-1·49) 35 (14·7) 55 (23·1) 128 (53·8) 13 (5·4) 3 (1·3) 1 (0·4) 3 (1·3) 
rAsp f 15 0·95 (0·54-1·76) 38 (16) 40 (16·8) 125 (52·5) 20 (8·4) 5 (2·1) 5 (2·1) 5 (2·1) 
rAsp f 17 0·88 (0·52-1·63) 37 (15·5) 52 (21·9) 118 (49·6) 12 (5) 9 (3·8) 3 (1·3) 7 (2·9) 
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Table E2 
Allergen 
Median sIgE (IQR) kU/L 
  Matched cohorts 
    Bronchiectasis Bronchiectasis Bronchiectasis 
  
Allergic rhinitis Bronchiectasis  (SG-KL) (SG-KL) (DD) 
p-value 
n=149 n=238 n=138 n=100 n=100 
House  dust mite 
Der p 0·68 (0·22-2·75) 2·28 (1·16-9·32) 2·75 (1·29-15·83) 2·70 (1·33-17·19) 1·87(1·05-4·27) 0·007 
Blo t 0·59 (0·24-1·54) 2·33 (1·12-9·27) 2·82 (1·12-14·05) 2·91 (1·15-17·78) 2·06 (1·19-5·79) 0·21 
Alternaria Alt a 0·37 (0·18-0·70) 0·74 (0·39-1·30) 0·63 (0·33-1·12) 0·65 (0·33-1·13) 0·89 (0·58-1·34) 0·015 
Aspergillus  
Major 
rAsp f 1 0·37 (0·28-0·73) 0·82 (0·33-2·51) 1·09(0·50-2·78) 1·18(0·50-3·01) 0·62 (0·29-1·86) 0·009 
rAsp f 2 0·37 (0·25-0·66) 0·91 (0·52-1·59) 0·88 (0·47-1·56) 0·92 (0·52-1·76) 0·93 (0·58-1·63) 0·771 
Minor 
rAsp f 6 0·52 (0·33-0·96) 0·81 (0·46-1·42) 0·78 (0·37-1·42) 0·79 (0·43-1·43) 0·97 (0·62-1·43) 0·112 
rAsp f 8 0·26 (0·15-0·56) 0·86 (0·51-1·49) 0·78 (0·41-1·47) 0·81 (0·49-1·50) 0·97 (0·68-1·53) 0·105 
rAsp f 15 0·29 (0·16-0·56) 0·95 (0·54-1·76) 0·87 (0·43-1·67) 0·89 (0·55-1·63) 1·08 (0·70-1·97) 0·124 
rAsp f 17 0·38 (0·18-0·84) 0·88 (0·52-1·63) 0·78 (0·42-1·61) 0·80 (0·47-1·69) 1·06 (0·69-1·77) 0·021 
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Table E3 
 
 
 
 
 
 
 
  
Allergen 
Patients with sIgE titres of class 3 or above (≥3·5 kU/L); n (%) 
  Matched cohorts 
    Bronchiectasis Bronchiectasis Bronchiectasis 
Allergic rhinitis Bronchiectasis  (SG-KL) (SG-KL) (DD) 
n=149 n=238 n=138 n=100 n=100 
House  dust mite 
Der p 33 (22%) 91 (38%) 63 (46%) 46 (46%) 28 (28%) 
Blo t 17 (11%) 98 (41%) 60 (44%) 46 (46%) 38 (38%) 
Alternaria Alt a 1 (1%) 17 (7%) 11 (8%) 9 (9%) 6 (6%) 
Aspergillus  
Major 
rAsp f 1 3 (2%) 41 (17%) 29 (21%) 23 (23%) 12 (12%) 
rAsp f 2 0 30 (13%) 16 (12%) 13 (13%) 14 (14%) 
Minor 
rAsp f 6 0 21 (9%) 13 (9%) 9 (9%) 8 (8%) 
rAsp f 8 0 20 (8%) 10 (7%) 7 (7%) 10 (10%) 
rAsp f 15 1 (1%) 35 (15%) 21 (15%) 15 (15%) 14 (14%) 
rAsp f 17 5 (3%) 31 (13%) 14 (10%) 10 (10%) 17 (17%) 
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 Table E4 
Allergen  
SG-
KL  
DD  
Median FEV1 Median Exacerbations sABPA  n (%) 
 
SG-KL  DD SG-KL  DD SG-KL  DD 
sIgE class p-
value 
sIgE class p-
value 
sIgE class p-
value 
sIgE class p-
value 
sIgE class p-
value 
sIgE class p- 
value 
Effect on 
clinical 
outcome < 3  
≥ 
3 
< 3  
≥ 
3 
< 3  ≥ 3 < 3  ≥ 3 < 3  ≥ 3 < 3  ≥ 3 
House  dust mite 
Der p 
↑↑ ↑ 
76 61 0·039* 77 72 0·47 1 1 0·925 3 3 0·47 
10 
(13%) 
12 
(19%) 
0·484 
15 
(21%) 
6 
(21%) 
1 
Decreased 
FEV1 in SG-KL 
Blo t 75 61 0·04* 78 75 0·40 0 1 0·908 3 3 0·86 
8 
(12%) 
14 
(26%) 
0·059 
11 
(18%) 
10 
(26%) 
0·323 
Alternaria Alt a ↑ ↑↑ 68 84 0·31 76 65 0·47 1 1 0·777 3 5 0·14 
19 
(15%) 
3 
(33%) 
0·382 
19 
(20%) 
2 
(33%) 
0·603 - 
Aspergillus  
Major 
rAsp f 1 ↑↑ ↑ 69 62 0·16 77 55 0·028* 1 0 0·407 3 1·5 0·39 
17 
(16%) 
5 
(17%) 
0·782 
19 
(22%) 
2 
(17%) 
1 
Decreased 
FEV1 in DD 
rAsp f 2 ↑ ↑ 69 66 0·48 77 67 0·17 0 1 0·617 3 3 0·46 
17 
(14%) 
5 
(31%) 
0·137 
16 
(19%) 
5 
(36%) 
0·164  - 
Minor 
rAsp f 6 ↑ ↑↑ 70 57 0·49 76 67 0·65 0 1 0·144 3 3·5 0·46 
18 
(14%) 
4 
(31%) 
0·223 
19 
(21%) 
2 
(25%) 
0·673  - 
rAsp f 8 ↑ ↑↑ 70 56 0·18 76 75 0·93 0 1·5 0·308 3 1 0·42 
18 
(14%) 
4 
(40%) 
0·054 
20 
(22%) 
1 
(10%) 
0·684 - 
rAsp f 15 ↑ ↑↑ 70 57 0·12 76 75 0·53 0 1 0·205 3 2 0·73 
15 
(13%) 
7 
(33%) 
0·045* 
16 
(19%) 
5 
(36%) 
0·164 
Increased 
exacerbations in 
SG-KL 
rAsp f 17 ↑ ↑↑ 69 65 0·83 78 69 0·16 0 1·5 0·035* 3 3 0·80 
16 
(13%) 
6 
(43%) 
0·011* 
16 
(19%) 
8 
(47%) 
0·008** 
Increased in 
sABPA 
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Table E5 
Characteristic 
 
Immuno-allertype 
FDPI HDCD p-value 
BSI score : median (IQR) 10 (7-13) 8 (6-12) 0.0098 
BSI status : (%)     0.0245 
Severe 65  47  
 Moderate 29  40  
Mild 6  13  
 FEV1 % predicted:  median (IQR) 68 (50-86) 80 (62-90) 0.0114 
Aetiology (%)   0.0213 
Idiopathic 54  71   
Post-infection 36  19   
Other 10  10   
Long-term antibiotics (%)   0.0620 
All  25  14  
Macrolide 19 13 0.2729 
Sputum galactomannan (OD450) 0.299 (0.07-1.08) 0.115 (0.05-0.94) 
 
0.0645 
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Supplementary Table E1: Median specific-IgE (sIgE) titre (by class) against a range of 
recombinant allergens (house dust mite, Alternaria and Aspergillus) in non-CF bronchiectasis. 
Data are presented as median (interquartile range; IQR) and number of patients (n) 
(percentage; %). 
 
Supplementary Table E2: Specific-IgE (sIgE) titres against house dust mite, Alternaria 
alternata and Aspergillus fumigatus recombinant allergens in patients with allergic rhinitis 
(n=149) and bronchiectasis (n=238). The bronchiectasis cohorts SG-KL and DD (n=100 each) 
were matched for age, gender and disease severity. Data are presented as median 
(interquartile range; IQR) and p-values indicated relate to the differences observed between 
matched cohorts. 
 
Supplementary Table E3: Specific-IgE (sIgE) titres against house dust mite, Alternaria 
alternata and Aspergillus fumigatus recombinant allergens in patients with allergic rhinitis 
(n=149) and bronchiectasis (n=238) expressed as number and percentages of patients 
exhibiting specific-IgE (sIgE) titres of class 3 and above. As for Supplementary table E2, The 
bronchiectasis cohort includes SG-KL and DD cohorts (n=100 each) matched for age, gender 
and disease severity.  
 
Supplementary Table E4: Relationships between observed sensitization patterns against a 
variety of allergens (house dust mite: Der p and Blo t; A. alternata: Alt a and A. fumigatus: 
rAsp f 1, f 2, f 6, f 8, f 15, f 17) and clinical outcomes in bronchiectasis. ↑: elevated sIgE titre, 
↑↑: markedly elevated sIgE titre. Comparison of the effect of elevated sIgE titres on FEV1, 
exacerbations and sABPA presence is indicated for patients from both the SG-KL and DD 
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cohorts (n = 238) with p-values for each comparison indicated; *p<0·05, **p<0·01. The final 
column summarises the main effects seen for each allergen.  
 
Supplementary Table E5: Clinical characteristics of immuno-allertypes observed in NCFB. 
A comparison of clinically relevant outcomes among patients from the FDPI and HDCD 
immuno-allertype clusters is summarized. Only variables found to exhibit significant values 
of <0.1 are illustrated Significant differences in primary outcomes of interest were observed 
including BSI score/status and lung function (FEV1 % predicted). Immuno-allertypes 
exhibited differences in aetiology, while use of long-term antibiotics and observed sputum 
galactomannan levels were greater in the FDPI cluster.  
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